Non-Hodgkin lymphomas can be classified according to the speed at which they progress. Those that grow and spread slowly are described as ‘indolent’, one of the most common types of which is ...

Here are the details: An effective treatment, until it isn't: The UW–Madison team sought to understand why some patients with certain non-Hodgkin's lymphomas that originate in white blood cells ...

T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...

Doctors group B-cell lymphomas based on: How the cancer cells look under a microscope Whether the cancer cells have certain proteins on their surface What kinds of gene changes are inside the ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

Each year, about 100,000 patients worldwide are affected by T-cell leukemias and lymphomas. Adults with relapsed T-cell cancers have limited therapeutic options and five-year survival rates of 7 ...

The following is a summary of “Hematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre ...

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...

GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first ...

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.